Humacyte
NASDAQ: HUMAMorrisville, US · Delaware corporation · 3 known investors
Find your way into Humacyte
302 people in our graph share verified history with the Humacyte team — schools, employers, funds. One of them is your warm intro.
Noubar Afeyanunlockedknows Laura Niklason, MD, PhD · together at Massachusetts Institute of Technology (overlapped)
×3knows the team · via Yale University
knows the team · via Duke University
knows the team · via Massachusetts Institute of Technology
×6knows the team · via Massachusetts General Hospital
Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform. Its off-the-shelf vessels target vascular trauma, AV access, and peripheral artery disease (PAD), and have received FDA Regenerative Medicine Advanced Therapy designation.
Founders & leadership
LE
Laura E. NiklasoninFounderLaura Niklason, MD, PhD, founded Humacyte and serves as its Chief Executive Officer. She has conducted research in vascular and lung engineering and holds memberships in the National Academies of Engineering and Medicine.
LN
Laura Niklason, MD, PhDinFounderFounder of Humacyte, a regenerative medicine company developing a bioengineered human-derived Acellular Tissue Engineered Vessel and a scalable cell sourcing and manufacturing platform for vascular trauma, AV access, and peripheral artery disease.
TL
Ted LithgowinChief Commercial Officer2019–2019
PB
Paul BoyerinChief Financial Officer (CFO)2010–2018
CS
Carrie S. CoxExecutive
Board
RA
Robert AndersonBoard director
RL
Robert LangerBoard director
BW
Brady W. DouganBoard director
MW
Max WallaceBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$274.8M disclosed across 3 of 4 rounds · 2007–2026
▶$150MraisedJun 2018 · 1 investors · BiotechnologyRule 506(b)
▶$150MraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey H. LawsonExecutive Officer
- Paul A. BoyerExecutive Officer
- Theodore D. LithgowExecutive Officer
- Robert S. LangerDirector
- Dale A. SanderDirector
- Robert AndersonDirector
- Carrie S. CoxExecutive Officer, Director
- William TenteExecutive Officer
- Brady W. DouganDirector
- Kathleen SebeliusDirector
- Laura E. NiklasonDirector
- Max N. WallaceDirector
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$75MraisedMar 2018 · 29 investors · BiotechnologyRule 506(b)
▶$75MraisedMar 2018 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Carrie S. CoxExecutive Officer, Director
- Max WallaceDirector
- Paul BoyerExecutive Officer
- Laura NiklasonDirector
- Brady W. DouganDirector
- Robert AndersonDirector
- Theodore LithgowExecutive Officer
- Kathleen SebeliusDirector
- Dale A. SanderDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$49.8MraisedJan 2015 · 6 investors · BiotechnologyRule 506(b)
▶$49.8MraisedJan 2015 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert AndersonDirector
- Robert LangerDirector
- Ted LithgowExecutive Officer
- Laura E. NiklasonDirector
- Brady W. DouganDirector
- Max WallaceDirector
- Paul A. BoyerExecutive Officer
- Carrie S. CoxExecutive Officer, Director
- Offering amount
- $73.8M
- Amount sold
- $49.8M
- First sale
- Oct 2007
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Humacyte went on to found or lead other companies.
Competitors · 6
by search overlap
Seeking Alpha24 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits19 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall St18 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Robinhood17 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView16 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks16 shared keywordsFinancial analysis and stock research platform.
Companies competing with Humacyte for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Humacyte posts $0.9M revenue, $54M net loss | HUMA Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Humacyte do?
- Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform. Its off-the-shelf vessels target vascular trauma, AV access, and peripheral artery disease (PAD), and have received FDA Regenerative Medicine Advanced Therapy designation.
- Who founded Humacyte?
- Humacyte was founded by Laura E. Niklason, Laura Niklason, MD, PhD.
- Who are Humacyte's investors?
- Humacyte's investors include First In Ventures, Fresenius Medical Care Ventures, Oberland Capital.
- How much funding has Humacyte raised?
- Humacyte has disclosed $274.8M raised across 3 of its 4 known rounds.
- Where is Humacyte headquartered?
- Humacyte is headquartered in Morrisville, US.